






















































































































WIRKLICHES NEULAND IN EINER WISSENSCHAFT 
KANN WOHL NUR GEWONNEN WERDEN, 
WENN MAN AN EINER ENTSCHEIDENDEN STELLE 
BEREIT IST, DEN GRUND ZU VERLASSEN, 
AUF DEM DIE BISHERIGE WISSENSCHAFT RUHT, 
UND GEWISSERMASSEN INS LEERE ZU SPRINGEN. 


















































































































































































































































































































































































































































In	2011,	 roughly	450	 in	100	000	 individuals	were	newly	diagnosed	with	 cancer	 [1].	The	most	







































disease.	 Acute	 leukemias	 end	 lethal	 within	weeks,	 if	 not	 treated	 immediately	 [7].	 In	 contrast,	
chronic	 leukemias	 typically	 develop	 over	 a	 longer	 period	 of	 time	 and	 progress	 slowly	 [8].	
Additionally,	 both	 acute	 and	 chronic	 leukemia	 can	 be	 subdivided	 into	 lymphocytic	 and	
myelogenous	forms,	according	to	the	type	of	affected	blood	cells.	While	lymphocytic	forms	arise	
in	 progenitor	 cells	 of	 lymphocytes,	 myelogenous	 forms	 affect	 myeloid	 cells	 which	 normally	









determined.	Especially	 ionizing	radiation	contributes	 significantly	 to	acute	 leukemias	 [10],	 but	
also	 chemicals,	 such	 as	 pesticides	 [11]	 or	 benzenes	 [12]	 increase	 the	 risk	 for	 leukemia.	













gene	 with	 a	 strong	 promoter	 or	 the	 fusion	 protein	 has	 different	 functions,	 the	 cell	 can	 be	
transformed	to	a	tumor	cell.	
Interestingly,	 particular	 translocations	 are	 associated	 with	 certain	 leukemias	 [16].	 The	 most	
prominent	 example	 is	 the	 CML‐related	 Philadelphia	 chromosome,	 which	 is	 the	 result	 of	 a	
reciprocal	translocation	of	chromosomes	9	and	22	(t(9;22)(q34;q11)).	This	translocation	fuses	
the	ABL	gene	(Abelson	murine	 leukemia	viral	oncogene	homolog	1)	to	the	BCR	gene	(breakpoint	


















































to	 develop	 AML	 and	 rarely	 ALL	 [28].	 Moreover,	 MLL	 translocations	 differ	 from	 other	
translocations	in	that	both	of	the	two	fusion	genes	generated	by	the	reciprocal	translocation	were	























cyclophilin	 CYP33	 [33].	 In	 the	C‐terminal	 region	 of	 the	MLL	protein,	 a	 transactivation	domain	
interacting	with	CREB‐binding	protein	(CBP)	is	found,	as	well	as	a	SET	(Su(var)3‐9,	enhancer‐of‐
zeste,	trithorax)	domain	with	histone	H3K4	methyltransferase	activity.	
With	 the	 help	 of	 these	 domains,	 MLL	 functions	 as	 transcriptional	 regulator.	 In	 particular,	 it	















































among	 all	 MLL	 homologs,	 including	 the	 human	 MLL2	 protein	 and	 the	 trithorax	 protein	 in	
Drosophila	melanogaster,	CS1	is	present	only	in	vertebrates.	Subsequently,	the	protease	for	MLL	
cleavage	was	discovered.	Due	to	the	threonine	as	its	active	site	residue	and	the	specific	cleavage	
after	 aspartate,	 this	 protease	was	 named	 threonine	 aspartase	 1	 (Taspase).	 Taspase	 is	 able	 to	




























































MLL	 protein.	 As	 a	 member	 of	 the	 type	 II	 asparaginase	 family,	 Taspase	 displays	 the	 typical	







a	 Overlay	 of	 the	 crystal	 structure	 of	 Taspase	 (red;	 PDB	 2a8j)	 with	 human	 asparaginase	 (4gdw),	 plant	


























folding	 helper	 [60].	 The	 autocatalytic	 proteolytic	 processing	 of	 the	 type	 II	 asparaginase	
proenzymes	 has	 been	 elucidated	 in	 detail	 [61,62].	 In	 short,	 the	 catalytic	 threonine	 side	 chain	
attacks	the	peptide	bond	to	the	preceding	aspartate,	before	the	protein	backbone	and	side	chain	





















threonine	 to	 valine	 does	 not	 only	 prevent	 the	 autocatalytic	 activation	 event,	 but	 also	 renders	
Taspase	unable	to	cleave	its	substrates	in	trans	[56,57].	
After	 autoprocessing,	 the	α‐	 and	β‐subunits	 form	a	 heterodimer,	 and	 two	of	 these	 dimers	 are	
supposed	 to	 assemble	 to	 a	 hetero‐tetramer	 (figure	 1.7b;	 [64]).	 The	 resulting	 αββα	 fold	 after	
autoprocessing	is	a	common	feature	of	all	Ntn	hydrolases	despite	very	low	sequence	similarity	
and	 was	 described	 for	 glycosylasparaginase	 [65],	 plant	 asparaginase	 [66],	 and	 the	 only	 other	
threonine	protease	 in	 the	Ntn	 family,	 the	 proteasome	 [67].	 However,	 the	 formation	 of	 a	 αββα	
shaped	 hetero‐tetramer	 in	 solution	 is	 controversially	 discussed	 for	 Taspase,	 as	 analytical	 gel	
filtrations	 indicate	 the	 presence	 of	 Taspase	 as	 heterodimer	 and	 enforced	 dimerization	 could	
effectively	inhibit	Taspase	in	cells	[68].	



































bipartite	 nuclear	 localization	 signal	 [74].	 However,	 closer	 investigation	 revealed	 a	 dynamic	
shuttling	process	between	nucleus	and	cytoplasm.	The	nuclear	import	via	a	nuclear	localization	
signal	 (NLS)	 is	 mediated	 by	 importin‐α	 and	 could	 also	 be	 confirmed	 for	 the	 proenzyme.	 In	
















This	 permissive	 role	 of	 Taspase	 in	 leukogenesis	was	 corroborated	 by	 the	 finding	 that	mouse	
embryonic	fibroblasts	(MEFs)	lacking	Taspase	are	resistant	to	oncogenic	transformation	induced	
by	Myc,	 E1A,	 RAS,	 and	 p53	 [76].	Moreover,	 Taspase‐deficient	mice	 exhibited	 decreased	 cyclin	
levels	 as	 well	 as	 increased	 expression	 of	 cyclin	 dependent	 kinase	 (CDK)	 inhibitors	 and	 thus	
showed	 a	 disrupted	 cell	 cycle	 [72].	 Additionally,	 Taspase	 expression	 is	 upregulated	 in	 many	
human	 cancers	 as	 well	 as	 cancer	 cell	 lines	 and	 required	 for	 tumor	 maintenance.	 Generally,	
increased	Taspase	 levels	 correlate	with	a	dependency	on	Taspase	expression	 [72,76].	Of	note,	
recent	 studies	 imply	 a	 crucial	 role	 of	 Taspase	 not	 only	 in	 leukemia,	 but	 also	 in	 solid	 tumors	
[57,70,76].	 Consequently,	 Taspase	 knockdowns	 in	 these	 tumors	 cause	 a	 disruption	 of	






















HSP90	client	proteins	are	crucial	 for	 the	regulation	of	cell	 survival,	 cell	growth,	cell	 cycle,	and	
apoptosis,	tumor	cells	relying	on	these	client	proteins	are	effectively	hit	by	the	HSP90	inhibitor	
geldanamycin™	 [77].	 Furthermore,	 Luo	 and	 colleagues	 reported	 that	 inhibition	 of	 the	 non‐
oncogene	polo‐like	kinase	1	(PLK1)	is	toxic	for	cells	with	mutated	Ras	oncogene	[78].	Moreover,	
also	the	proteasome	inhibitor	bortezomib	can	be	regarded	as	a	non‐oncogene	addiction	drug.	It	is	
active	 against	 a	 variety	 of	 tumors,	 including	myeloma,	 CLL,	 prostate	 and	 colon	 cancer,	 and	 is	
approved	for	treating	multiple	myeloma	and	mantle	cell	lymphoma	[79].	Tumor	cells	acquire	a	









As	 non‐oncogene	 addiction	 protease,	 Taspase	 is	 of	 high	 interest	 for	 cancer	 therapy,	 since	
inhibition	 of	 Taspase	 is	 considered	 a	 promising	 way	 to	 prevent	 leukemogenesis.	 However,	
inhibition	of	Taspase	activity	is	not	trivial,	as	Taspase	is	insensitive	against	inhibition	by	general	
serine,	 cysteine,	 or	 metalloprotease	 inhibitors	 [57].	 Hence,	 different	 approaches	 were	


























Besides	 compound	 library	 screening,	 inhibitors	 can	be	derived	 from	 the	 substrate	 by	 rational	
design	(figure	1.11c).	Regarding	this,	 the	Bogyo	group	developed	a	series	of	substrate‐derived	
































Nevertheless,	 the	 progressive	 usage	 of	 nanoparticles	 is	 controversially	 discussed,	 as	
nanoparticles	 taken	up	via	 the	skin,	 lung,	and	gut	are	distributed	by	the	bloodstream	 [90]	and	
possible	hazards	and	long‐term	influences	are	insufficiently	researched	[90].	Especially	the	long	
retention	half‐times	of	 inhaled	nanoparticles	 in	 the	alveolar	region	of	70	days	 in	rats	and	 two	
years	in	humans	[91]	pose	a	threat	to	cells,	since	nanoparticles	are	internalized	by	endocytosis	
[92].	Once	the	particles	are	inside	the	cell,	they	can	generate	reactive	oxygen	species	(ROS)	[93],	
disrupt	membranes	 [94],	 cause	protein	aggregation	 [95],	 interfere	with	 cellular	pathways	 [96],	
unfold	proteins	[97],	or	intercalate	into	DNA	[98].	
On	the	other	hand,	the	interaction	with	biomolecules	and	the	nano‐bio‐interface	is	of	high	interest	























Recently,	 a	 gold	 nanoparticle‐based	 immunoassay	 was	 described	 to	 detect	 the	 Alzheimer’s	
disease	 related	β‐amyloid	peptide	 in	 cerebrospinal	 fluids	 [107].	 Even	 lung	 cancer	diagnosis	 in	
exhaled	 breath	 was	 reported.	 For	 this,	 chemiresistors	 (microsensors)	 based	 on	 5	 nm	 gold	
nanoparticles	covered	with	different	organic	substances	were	used	to	quantify	volatile	organic	
compounds	in	the	exhaled	breath	[108].	
The	 versatile	 applicability	 of	 nanoparticles	 furthermore	 allows	 the	 inhibition	 of	 enzymes,	 as	








Although	the	survival	rates	 for	 leukemia	have	significantly	 improved	in	the	 last	decades	 [110],	




of	 certain	 types	 of	mixed	 lineage	 leukemia	 (MLL)	 and	 is	 upregulated	 in	 various	 solid	 tumors	
[71,76].	In	this	respect,	these	tumors	are	highly	dependent	on	Taspase	and	thus	hypersensitive	to	
a	loss	of	Taspase	activity	[76].	Despite	first	achievements	in	the	direction	of	Taspase	inhibitors,	
the	 compounds	originating	 from	 these	 studies	 exhibit	 either	weak	 inhibition	 [69,71]	 or	 broad	
bioactivities	[63].	Hence,	potent	Taspase	inhibitors	are	still	of	paramount	importance.	
To	develop	 novel	 Taspase	 inhibitors,	 a	 comprehensive	 analysis	 of	 the	 biochemical	 properties,	
such	as	activity,	substrate	specificity,	and	stability,	 is	helpful	and	can	give	deeper	 insights	 into	
Taspase‐mediated	catalysis.	To	this	end,	Taspase	as	well	as	active	and	inactive	mutants	will	be	
characterized.	Moreover,	 the	 structure	 of	 the	 long	 loop	 regions	 lacking	 in	 the	 Taspase	 crystal	














































































































































































Laemmli	buffer	 0.1 %	SDS,	0.303 %	Tris,	1.441 %	glycine,	ddH2O	
Coomassie	staining	solution	 1.25 g	Coomassie	brilliant	blue	G250,	227	ml	ethanol,	46	ml	
acetic	acid,	227	ml	ddH2O	
Coomassie	destaining	solution	 50 ml	acetic	acid,	75 ml	ethanol,	875 ml	ddH2O	
PBS	 137 mM	NaCl,	2.7 mM	KCl,	10 mM	NaH2PO4,	2	mM	KH2PO4,	
ddH2O	
TBST	buffer	 50 mM	Tris‐HCl,	150 mM	NaCl,	1 %	Tween‐20,	ddH2O,	pH	7.5
TAE	buffer	 40 mM	Tris	pH 8.5,	1 mM	EDTA,	20 mM	acetic	acid,	ddH2O
Lysis	buffer	 25 mM	Tris	pH	7.4,	150 mM	KCl,	5 mM	MgCl2,	5	%	glycerol,	1 %	
Triton	X‐100,	2	mM	2‐mercaptoethanol,	1	mM	PMSF,	1	tablet	
cOmplete,	ddH2O	
GST	wash	buffer	 50 mM	NaH2PO4,	450 mM	NaCl,	1 mM	DTT,	1	%	Triton	X‐100,	
pH	7.3	
GST	elution	buffer	 50 mM	NaH2PO4,	450 mM	NaCl,	1 mM	DTT,	20	mM	glutathione,	
pH	8.0	
GST	equilibration	buffer	 50 mM	NaH2PO4,	450 mM	NaCl,	1 mM	DTT,	1	%	Triton	X‐100,	
pH	7.3	
NiNTA	equilibration	buffer	 50 mM	NaH2PO4, 450 mM	NaCl,	10 mM	imidazole,	pH	8.0	
NiNTA	wash	buffer	 50 mM	NaH2PO4,	450 mM	NaCl,	20 mM	imidazole,	pH	8.0	
NiNTA	elution	buffer	 50 mM	NaH2PO4,	450 mM	NaCl,	250 mM	imidazole,	pH	8.0
Gel	filtration	buffer	 50 mM	NaH2PO4,	450 mM	NaCl,	1 mM	DTT,	pH	7.9	
Activity	assay	buffer	 50 mM	NaH2PO4,	10 %	sucrose,	1 mM	DTT,	pH	7.9	
50x	TS2	 2.4 mM	ZnSO4,	0.15 mM	MnCl2,	4.9 mM	H3BO3,	0.84	mM	CoCl2,	
0.84	mM	NiCl2,	58	µM	CuCl2,	4.3	mM	Na2MoO4,	0.12	mM	Na2SeO4,	
ddH2O	
LB	medium	 1 %	tryptone,	0.5 %	yeast	extract,	1 %	NaCl,	ddH2O,	pH	7.0
LB	agar	plates	 500 ml	LB	medium,	7.5 g	agar
M9	medium	 0.68 %	Na2HPO4,	0.3 %	KH2PO4,	0.05 %	NaCl,	0.1	%	NH4Cl,	0.2 %	
1	M	MgSO4,	0.2	%	50x	TS2,	0.1	%	10	mM	iron(III)	citrate,	0.4	%	
glucose,	0.01	%	CaCl2,	0.01	%	0.5	%	vitamin	B1,	ddH2O	
Nutrient	medium	 0.5 %	peptone,	0.3 %	meat	extract,	ddH2O	
SOC	medium	 2 %	tryptone,	0.5 %	yeast	extract,	10 mM	NaCl,	2.5	mM	KCl,	
10	mM	MgCl2,	10	mM	MgSO4,	20	mM	glucose,	ddH2O	
Hela	medium	 10 %	FCS,	1 %	MEM,	1 %	penicillin‐streptomycin,	DMEM	





















































































































































































Vector	maps	of	 the	plasmids	used	 in	 this	work	can	be	 found	 in	 the	supplement	(supplemental	
figure	 7.1	 and	 figure	 7.2).	 The	 plasmid	with	 human	 Taspase	 cDNA	 and	 Taspase	 plasmids	 for	
eukaryotic	transfection	were	courtesy	of	the	Knauer	group	and	the	pRARE2	plasmid	was	courtesy	
of	 the	 Ehrmann	 group.	 For	 cloning	 with	 GST	 tag,	 a	 modified	 pET‐41b(+)	 vector	 (Merck,	
Darmstadt)	was	used.	In	this	vector,	a	PreScission	cleavage	site	and	an	ApaI	cleavage	site	were	
inserted	in	the	multiple	cloning	site	after	the	GST	tag	between	the	BamHI	and	SacII	cleavage	sites.	


















































active	 site	 (D233A	 and	 T234A)	 prevent	 autocatalytic	 activation	 of	 the	 proenzyme	 and	 hence	
reduce	 catalytic	 activity.	 These	 mutations	 were	 inserted	 with	 the	 help	 of	 a	 QuikChange	 kit	
(Agilent,	 Santa	 Clara)	 using	 wild	 type	 Taspase	 as	 template.	 Primers	 were	 designed	 with	












































The	 construct	 for	 the	 GST‐tagged	 Taspase	 loop	 comprising	 56	 amino	 acids	 (G178‐D233)	was	













Forward	 5’-CACACAGGGCCCGGAATACCGTCTTGCCCTCC-3’ 59.5 








pET‐41‐PreSc	DNA	 2	(=300 ng) ‐
Loop	DNA	 ‐	 8	(=2 µg)
ApaI	 1	(=1 FDU) 1	(=1 FDU)























































































Chemically	 competent	 cells	 were	 incubated	with	 1	 µl	 of	 plasmid	 DNA	 for	 20	minutes	 on	 ice,	
followed	by	a	heat	shock	at	42	°C	for	45	seconds	and	another	incubation	step	on	ice	for	2	minutes.	
After	that,	the	cells	were	transferred	to	300	µl	of	SOC	medium	and	incubated	for	60	minutes	at	

















pellets	 were	 resuspended	 in	 50	 mM	 NaH2PO4,	 450	 mM	 NaCl,	 10	 mM	 imidazole,	 pH	 8.0	
















co‐transformed	 additionally	 to	 the	 Taspase	 construct	 (in	 pET‐22b	 vector)	 into	BL21(DE3)T1r	
chemically	competent	cells	(section	2.3.2).	Plating	on	LB	medium	with	140	µg/ml	ampicillin	and	
50	 µg/ml	 chloramphenicol	 allowed	 for	 selection	 of	 cells	 that	 had	 taken	 up	 both	 the	 Taspase	













15	 min)	 and	 resuspended	 in	 4	 l	 of	 M9	 minimal	 medium	 supplemented	 with	 15N	 ammonium	
chloride	and/or	13C	glucose.	Bacterial	growth	was	allowed	to	continue	at	37	°C,	160	rpm.	
For	 both	 labeled	 and	 unlabeled	 Taspase	 protein	 expression,	 at	 OD600	 of	 0.8,	 expression	 was	
induced	by	addition	of	200	µM	IPTG	and	the	temperature	was	reduced	to	30	°C.	6	h	after	induction,	
cells	were	pelleted	at	4	°C,	6300	g	for	20	minutes	and	resuspended	in	50	mM	NaH2PO4,	450	mM	
NaCl,	 10	mM	 imidazole,	 pH	8.0.	 The	Taspase	 loop	was	 expressed	 over	 night	 at	 25	 °C	 and	 the	
bacteria	pellet	was	resuspended	in	50	mM	NaH2PO4,	450	mM	NaCl,	1	mM	DTT,	1	%	Triton	X‐100,	




Cervical	 cancer	 cells	 (Hela)	were	 cultivated,	 cryopreserved	 and	 passaged	 as	 suggested	 by	 the	
American	Type	Culture	Collection	(ATCC):	Cells	were	cultivated	in	10	cm	dishes	with	10	ml	cell	
culture	medium	and	split	at	70	to	90	%	confluency.	For	this,	cells	were	washed	with	PBS,	before	
1	ml	 of	 trypsin‐EDTA	was	 added	 and	 the	 cells	were	 incubated	 for	 5	minutes	 to	 detach.	 9	ml	
prewarmed	medium	was	added	and	cells	were	dispersed,	prior	to	seeding	in	a	split	ratio	of	1:5	to	
1:25	in	fresh	medium.	Medium	was	changed	as	needed.	For	cryopreservation,	2x106	cells/ml	were	








































Hoechst	 345	nm	 455 nm 25 ms
GFP	 480	nm	 510 nm 500 ms




using	 the	 DAPI	 channel.	 The	 area	 of	 the	 cell	 borders	 minus	 the	 nucleic	 area	 was	 defined	 as	
cytoplasm.	The	average	intensities	of	the	nucleic	and	cytoplasmic	areas	were	calculated,	and	the	





Uptake	 of	 rhodamine‐labeled	 peptidic	 inhibitor	 was	 assayed	 with	 Hela	 cells.	 5	 µM	 or	 50	 µM	
fluorescent	inhibitor	were	added	to	2x105	cells	in	12	well	plates.	Cells	were	either	cultivated	in	
medium	 with	 or	 without	 serum	 and	 fixated	 1	 or	 5	 hours	 after	 addition	 of	 the	 inhibitor.	
Fluorescence	microscopy	 images	were	 taken	as	described	above	 (section	2.3.7)	using	 the	RFP	


















Affinity	 chromatography	was	 performed	with	 an	Äkta‐FPLC	 system	 (GE	Healthcare,	 Solingen)	


















150 ml 1 ml/min	 ‐	






100 ml 1 ml/min	 3	ml	













Step	 Buffer	 Volume Flow	rate	 Size	of	
collected	
fractions	












5 ml 1 ml/min	 ‐	



















150 ml 1 ml/min ‐
Wash	 GST	wash	buffer	 100 ml 1 ml/min ‐
Elution		 GST	elution	buffer	 100 ml 1 ml/min 3 ml	
	
Although	the	Taspase	loop	itself	does	not	absorb	light	at	280	nm	due	to	its	lack	of	tyrosines	and	
tryptophans,	 the	absorbance	of	 the	GST	 tag	 can	be	used	 to	 identify	protein	 containing	elution	
fractions.	These	fractions	were	concentrated	in	a	Centricon	with	10	kDa	cut‐off	to	a	final	volume	
of	5	ml.	Protein	concentration	was	determined	using	UV/Vis	spectroscopy,	assuming	an	extinction	



















Protein	 concentrations	of	 eukaryotic	 cell	 lysates	were	determined	 in	a	Bradford	assay.	1	µl	of	
sample	was	incubated	with	999	µl	Bradford	reagent	for	5	minutes	and	absorbance	was	measured	








combination	 of	 absorbance	 and	 fluorescence	 spectroscopy.	 This	 was	 necessary,	 because	 the	
concentrations	were	 too	 low	 to	 be	 detected	 by	 absorbance	 spectroscopy.	 In	 a	 first	 step,	 cells	
transfected	with	only	GFP	were	lysed	and	the	GFP	concentration	in	the	 lysate	was	determined	
with	 a	 Nanodrop	 ND	 1000	 applying	 an	 extinction	 coefficient	 of	 9500	 M‐1	 cm‐1	 at	 475	 nm.	
Transfection	 and	 expression	 is	 much	 more	 efficient	 for	 GFP	 than	 for	 GFP‐Taspase	 and	 a	
concentration	of	15.8	µM	GFP	in	the	cell	lysate	was	calculated.	From	this	lysate,	a	standard	curve	




Concentrations	 of	 the	 peptidic	 substrate	 used	 in	 the	 kinetic	 assays	 were	 determined	 via	 the	
absorbance	 of	 the	 anthranilic	 acid.	 An	 extinction	 coefficient	 of	 14650	 M‐1	 cm‐1	 at	 355	 nm	
wavelength	 was	 used.	 The	 concentration	 of	 the	 rhodamine‐labeled	 inhibitor	 was	 determined	
likewise,	assuming	an	extinction	coefficient	of	80000	M‐1	cm‐1	at	555	nm	[123].	











wt	Taspase	 26930	M‐1	cm‐1 45	278	Da 420	
Inactive	Taspase	 26930	M‐1	cm‐1 45	204 Da 420	
Active	Taspase	 26930	M‐1	cm‐1 42	082 Da 399	
Taspase	loop	 0	M‐1	cm‐1	 6 611 Da 58	
	
2.4.5 SDS‐PAGE	
The	 composition	 of	 polyacrylamide	 gels	 for	 sodium	 dodecyl	 sulfate	 polyacrylamide	 gel	
electrophoresis	(SDS‐PAGE)	is	given	in	table	2.24.	Proteins	were	separated	for	about	90	minutes	






0.5	M	Tris,	pH	6.8	 500 µl ‐
1.5	M	Tris,	pH	8.0	 ‐ 4.4 ml
10	%	SDS	 50 µl 200 µl
Acrylamide/Bis‐acrylamide	 850 µl 10 ml
10	%	Ammonium	peroxydisulfate	(APS) 50 µl 200 µl
TEMED	 5 µl 8 µl
ddH2O	 3.5 ml 5.2 ml
	
2.4.6 Analytical	gel	filtration	
Analytical	 gel	 filtrations	 were	 performed	 with	 a	 BioRad	 DuoFlow	 FPLC	 system	 on	 a	
Superdex	 200	 10/300	 gel	 filtration	 column	 (GE	 Healthcare,	 Solingen).	 The	 column	 was	
equilibrated	with	30	ml	of	50	mM	NaH2PO4,	450	mM	NaCl,	1	mM	DTT,	pH	8.	180	µg	Taspase	was	
loaded	 into	 a	 140	 µl	 loop	 and	 separated	 with	 0.5	 ml/min	 flow	 rate.	 Due	 to	 the	 low	 protein	
concentration,	the	absorbance	of	the	peptide	bond	at	214	nm	was	used	to	evaluate	the	retention	

















ܦܱܮ ൌ 	 ܣହ଴ଵ ∙ 26930	ܯ
ିଵ	ܿ݉ିଵ
ሺܣଶ଼଴ െ ܣହ଴ଵ ∙ 0.51ሻ ∙ 120000	ܯିଵ	ܿ݉ିଵ	
ܿ ൌ 	 ܣଶ଼଴ െ ܣହ଴ଵ ∙ 0.511	ܿ݉	 ∙ 26930	ܯିଵ	ܿ݉ିଵ		
	
These	calculations	yielded	for	wild	type	Taspase	a	protein	concentration	of	551	µM	and	a	DOL	of	





changed	 for	 labeling	 to	 50	 mM	 NaH2PO4,	 450	 mM	 NaCl,	 pH	 7.4	 by	 repeated	 dilution	 and	
concentration	 in	 a	 30	 kDa	 cut‐off	 Centricon.	 A	 2.5‐fold	molar	 excess	 of	 Atto488	was	 used	 for	




ܦܱܮ ൌ 	 ܣହ଴ଵ ∙ 26930	ܯ
ିଵ	ܿ݉ିଵ
ሺܣଶ଼଴ െ ܣହ଴ଵ ∙ 0.1ሻ ∙ 90000	ܯିଵ	ܿ݉ିଵ	
ܿ ൌ 	 ܣଶ଼଴ െ ܣହ଴ଵ ∙ 0.11	ܿ݉	 ∙ 	26930	ܯିଵ	݈ିଵ		
	


























an	 additional	 anthranilic	 acid	 coupled	 to	 the	 N‐terminus	 and	 dinitrophenol‐conjugated	 lysine	
coupled	to	the	C‐terminus	of	the	peptide	(CASLO	ApS,	Lyngby).	The	fluorescent	dye	anthranilic	
acid	can	be	quenched	by	dinitrophenol.	Since	during	the	quenching	process	the	excited	electron	
transfers	 its	 excess	 energy	 to	 an	 electron	 of	 the	 quencher	molecule,	 the	 quenching	 efficiency	
depends	 on	 the	 distance	 between	 dye	 and	 quencher.	 The	 intact	 peptide	 is	 quenched	 very	
effectively,	i.e.	90	%	of	the	energy	absorbed	by	anthranilic	acid	is	transferred	to	dinitrophenol	and	













fitted	with	 linear	regression	and	converted	 to	enzyme	activity.	As	 fluorescence	 is	measured	 in	





prerequisite	 for	 this	 was	 that	 all	 measurements	 were	 taken	 with	 the	 same	 parameters	 with	
respect	 to	 temperature,	pH,	excitation	slit	width,	emission	slit	width,	PMT	voltage	and	sample	
purity.	Furthermore,	the	substrate	concentration	had	to	be	low	to	avoid	inner	filter	effects	and	
allow	 the	 assumption	 of	 a	 linear	 correlation	of	 intensity	 change	 and	 substrate	 cleavage.	 8	 µM	
proved	to	be	a	suitable	substrate	concentration	with	an	absorbance	well	below	0.1,	while	still	high	
enough	to	yield	an	adequate	time	to	measure	the	reaction	before	substrate	depletion	began.	


















Fluorescence	 intensities	 were	 recorded	 for	 8	 µM	 of	 the	 intact	 and	 the	 completely	 cleaved	
substrate.	 The	 measured	 intensities	 (I)	 in	 arbitrary	 units	 were	 converted	 to	 substrate	
concentrations	(c)	according	to	the	following	equation	
	














For	 the	determination	of	 the	Michaelis	constant	KM,	 the	 initial	velocities	 (v)	were	measured	at	
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aliquots	 of	 300	 nM	 Taspase	 in	 sucrose	 were	 flash	 frozen	 and	 stored	 at	 ‐80	 °C.	 For	 each	
measurement,	an	aliquot	was	thawed	rapidly	in	a	thermomixer	at	37	°C	and	incubated	for	exactly	
5	minutes	at	500	rpm	to	ensure	a	homogeneous	temperature.	After	the	incubation	time,	preheated	
Taspase	 was	 added	 to	 the	 equally	 preheated	 substrate	 mixed	 with	 inhibitor	 or	 buffer	 and	
immediately	 filled	 into	 cuvettes	 preheated	 to	 37	 °C.	 The	 first	 data	 point	 of	 each	 trace	 was	
measured	10	seconds	after	the	reaction	had	started.	
With	 this	 assay,	 several	 compounds	 were	 tested	 for	 inhibitory	 effects	 on	 Taspase	 activity.	
Together	with	the	substrate,	the	compounds	were	briefly	incubated	at	37	°C	as	described	above	
before	 Taspase	 was	 added.	 Some	 of	 the	 inhibitors	 tested	 were	 insoluble	 in	 water	 at	 higher	




For	 IC50	 fits,	 enzymatic	 activity	 of	 Taspase	 was	 plotted	 against	 logarithmic	 inhibitor	
concentrations	and	fitted	to	the	following	model.	
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Bottom	 and	 Top	 represent	 the	 inhibition	 at	 very	 low	 and	 very	 high	 inhibitor	 concentrations,	
respectively	and	IC50	is	the	concentration	at	which	50	%	of	the	effect	is	observed.	
For	 the	 experimental	 estimation	 of	 Ki	 values,	 the	 enzyme	 activity	 was	 measured	 at	 several	
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seen	 for	 noncompetitive	 inhibition.	 If	 Km	 and	 substrate	 concentration	 [S]	 is	 known,	 it	 is	 also	
possible	to	derive	the	Ki	value	from	IC50	values	using	the	Cheng‐Prusoff	equation	[124].	
	








ApS,	 Lyngby).	 Another	 negative	 control	 was	 performed	with	 inactive	 Taspase	 using	 identical	
parameters.	 For	 positive	 controls,	 a	 peptide	 comprising	 the	 CS1	 cleavage	 site	 of	 MLL	 was	











The	 principle	 of	 fluorescence	 anisotropy	 is	 based	 on	 photoselection.	 This	 means	 that	 after	
excitation	with	linear	polarized	light,	fluorophores	with	an	excitation	dipole	moment	parallel	to	
the	 electric	 vector	 of	 the	 incident	 light,	 are	 preferentially	 excited.	 In	 the	 excited	 state,	 the	
fluorophore	rotates	due	to	Brownian	motion.	The	degree	of	rotation	before	emission	depends	of	





parallel	 to	 the	 emission	 dipole	 of	 the	 fluorophore.	 Hence,	 the	 emitted	 light	 of	 a	 fast	 rotating	
















Parameter	 Atto488	 Atto594 Rhodamine Tryptophan	 Anthranilic	acid
Excitation	wavelength 501	nm	 601 nm 555 nm 280 nm 320	nm	
Emission	wavelengths 523	nm	 627 nm 582 nm 340 nm 420	nm	
Excitation	slit	width	 10	nm	 20 nm 5 nm 10 nm 20	nm	
Emission	slit	width	 20	nm	 20 nm 10 nm 20 nm 20	nm	
PMT	voltage	 400	V	 400 V 500 V 600 V 600	V	
Average	time	 5	s	 5 s 5 s 5 s 5	s	
Temperature	 20	°C	 20 °C 20 °C 20 °C 20	°C	
G	factor	 1.6724	 2.1338 1.9587 0.6537 1.1373	
Concentration	 1	µM	 1 µM 500 nM 10 µM 1	µM	
	
G	 factors	 were	 applied	 to	 compensate	 different	 transmission	 efficiency	 of	 the	 polarizers	 for	
horizontally	 and	 vertically	 polarized	 light.	 To	 obtain	 these	 values,	 the	 emission	 of	 every	
fluorophore	used	was	recorded	consecutively	with	polarizers	oriented	horizontally	and	vertically	
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Thermophoresis	 is	 the	directed	movement	of	particles	due	to	a	 temperature	gradient.	 In	most	
cases,	this	movement	occurs	from	hot	to	cold	and	depends	on	the	hydration	shell,	charge	and	size	
of	the	molecules.	If	binding	of	another	molecule	changes	any	of	these	three	parameters,	this	can	
be	 detected	 by	 microscale	 thermophoresis	 (MST;	 NanoTemper,	 Munich).	 The	 temperature	
gradient	 is	 generated	 by	 an	 infrared	 laser	 and	 the	movement	 of	 the	molecules	 is	 followed	by	
change	in	local	fluorescence	intensity	inside	a	capillary.	
Binding	 of	 Taspase	 to	 nanoparticles	 was	 assessed	 in	 standard	 glass	 capillaries	 with	 a	
Monolith	NT.115	during	 a	MST	demonstration	 course.	 Taspase	was	 labeled	with	Atto488	 and	
50	 nM	 labeled	 protein	 was	 added	 to	 a	 16‐step	 serial	 dilution	 of	 nanoparticles,	 ranging	 from	
200	µg/ml	to	12	ng/ml.	To	avoid	adsorption	of	Taspase	to	the	capillary	walls,	0.1	%	Tween	was	
added	to	a	buffer	containing	50	mM	NaH2PO4,	450	mM	NaCl,	1	mM	DTT,	pH	8.0	in	a	final	volume	
of	 40	 µl.	 Binding	 of	 the	 peptidic	 Taspase	 inhibitor	 Comp9	 was	 assessed	 under	 label‐free	







Fluorescence	 anisotropy	 is	 sensitive	 to	 changes	 in	 the	 hydrodynamic	 radius,	 as	 explicated	 in	
section	2.5.2.	Therefore,	it	can	be	used	as	a	measure	for	the	cleavage	of	fluorescent	substrates.	The	
stability	of	the	peptidic	rhodamine‐labeled	inhibitor	was	assayed	in	the	presence	of	1	µM	Taspase	















Excitation	wavelength 320	nm	 495 nm
Emission	wavelength	 420	nm	 582 nm
Excitation	slit	width	 20	nm	 20	nm
Emission	slit	width	 20	nm	 20	nm
PMT	voltage	 600	V	 600 V
Average	time	 5	s	 5 s
Interval	 10	min	 10 min


































parameters	used	 to	obtain	 the	melting	curves	 is	 listed	 in	 table	2.28.	Nonlinear	curve	 fitting	 to	





Parameter	 Value	 Parameter value
Start	 260	 Wavelength 225 nm
End	 200	 Temperature	slope 1 °C/min	
Scanning	mode	 Continuous	 Delay	time 180 s
Response	time	 0.5	s	 Response	time 8 s
Bandwidth	 2 nm	 Bandwidth 1 nm
Data	pitch	 0.2	nm	 Data	pitch 0.1 °C
















































































The	 principle	 of	 backbone	 atom	 assignment	 and	 identification	 of	 sequential	 amino	 acids	 is	
explained	here	using	simplified	example	spectra	(figure	2.5).	The	assignment	was	based	on	a	1H‐
15N	HSQC,	which	can	be	regarded	as	 the	 fingerprint	of	a	protein.	This	spectrum	shows	all	H‐N	
correlations,	which	 are	mainly	 backbone	 amide	 groups	 (figure	 2.5b),	 but	 also	 side‐chain	 H‐N	
groups	 of	 tryptophans,	 asparagines	 and	 glutamines	 are	 visible.	 Essentially,	 every	 amino	 acid	





acid	atoms,	shown	for	alanine	 in	a	polypeptide	chain.	Heavy	atoms	are	displayed	 in	black,	hydrogens	 in	
white.	c	3‐dimensional	HNCaCb	spectrum	showing	the	carbon	resonances	of	the	amino	acids	“a”,	“b”	and	
“c”.	 Alpha	 carbon	 atoms	 are	 displayed	 in	 blue,	 beta	 carbon	 atoms	 in	 red.	d	 3	 dimensional	 CbCaCONH	
spectrum	showing	the	carbon	resonances	of	the	amino	acids	preceding	amino	acids	“a”,	“b”	and	“c”.	Alpha	

























it	 is	possible	 to	determine	 that	 the	HSQC	peak	 labeled	as	 residue	 “b”	 is	 a	glycine,	but	 it	 is	not	
possible	to	determine	which	glycine	in	the	protein	caused	this	peak.	Furthermore,	the	order	of	the	
three	amino	acids	cannot	be	derived	from	these	spectra.	
















has	 both	Gly‐Ser‐Ala	 and	Gly‐Thr‐Ala	 in	 its	 sequence,	 or	 the	motif	 occurs	multiple	 times,	 it	 is	
necessary	 to	 assign	 longer	 fragments,	 before	 it	 can	be	unambiguously	 assigned	 to	 the	protein	
sequence.	Other	 spectra	 reveal	 information	 about	 the	 chemical	 shifts	 of	 side	 chain	 hydrogens	












conformations	 exist,	which	 is	 often	 observed	 as	 cis/trans	 conformations	 for	 amino	 acids	 near	












6220	 M‐1	 cm‐1,	 the	 NADH	 consumption	 per	 minute	 was	 calculated	 and	 the	 blank	 rate	 was	









cuvettes	with	 a	 Varian	 Cary	 100.	 In	 this	 assay,	 the	 blank	 rate	 of	 150	µM	 substrate	 peptide	 in	
presence	or	absence	of	nanoparticles	was	followed	at	390	nm	for	2	minutes,	before	the	reaction	
was	started	by	addition	of	350	nM	chymotrypsin.	After	baseline	subtraction,	the	comparison	of	





(Bruker	 Daltonics,	 Bremen).	 The	 matrix	 solution	 was	 created	 by	 dissolving	 7.6	 mg	 of	 2’,5’‐













Liquid	 chromatography‐mass	 spectrometry	 electrospray	 ionization	 time‐of‐flight	 mass	
spectrometry	(LC‐MS	ESI‐TOF	MS)	measurements	were	taken	with	an	LCQ	Fleet	ESI	spectrometer	
(Thermo	Scientific,	Darmstadt)	equipped	with	an	Eclipse	XDB‐C18	column	(Agilent,	Böblingen).	

























was	 generated	 in	 a	 stepwise	 approach.	 First,	 homology	models	 of	 the	 α‐	 and	 β‐subunit	 were	










identified	 using	 sphgen	 [127]	 and	 the	 active	 site	was	 selected	 as	 target	 area	 for	 docking.	 The	
overlapping	spheres	are	used	later	in	the	docking	process.	As	third	step,	a	square	box	with	50	Å	
edge	length	was	built	around	the	active	site.	In	this	box,	two	energy	grids	were	computed	using	
















the	 amount	 of	 structures	 and	 still	 cover	 a	maximum	 of	 different	 features,	 compounds	with	 a	
similar	 structure	were	 discarded.	 For	 this,	 the	 structures	were	 converted	 to	 chemical	 hashed	













































































terminal	 His‐tag	 was	 performed	 by	 Jens	 Rabenstein	 [82].	 The	 bicistronic	 construct	 for	 active	
Taspase	 with	 shortened	 loop	 (figure	 2.3)	 was	 designed	 in	 silico.	 The	 DNA	 was	 synthesized	
(GeneArt,	Regensburg)	and	subsequently	cloned	via	NdeI/XhoI	restriction	sites	into	a	modified	
pET‐41b	 vector	 [132,132].	 The	 catalytically	 inactive	 mutant	 D233A/T234A	 was	 created	 by	
QuikChange	according	to	manufacturer’s	instructions	using	the	construct	for	wild	type	Taspase	









primer	 pair	 given	 in	 table	 2.13.	 After	 PCR	 amplification,	 the	 PCR	 product	was	 analyzed	 in	 an	
agarose	gel	(figure	3.1).	A	band	at	approximately	150	bp	can	be	detected,	which	corresponds	to	
the	expected	size	of	168	bp	for	the	Taspase	loop.	This	band	was	cut	from	the	gel	and	the	DNA	was	
isolated.	Subsequently,	both	 the	 insert	 (PCR	product)	and	 the	vector	 (pET‐41b)	were	digested	
separately	with	ApaI	and	XhoI.	Insert	and	vector	were	purified	again,	before	they	were	ligated	(3	






































fraction	 is	present	 in	the	supernatant.	The	 largest	amount	of	soluble	Taspase	 is	achieved	after	
expression	for	6	h	at	30	°C	in	Rosetta2	cells.	Consequently,	 these	conditions	were	used	for	the	













The	 upper	 panel	 shows	 the	 chromatogram	 of	 the	 NiNTA	 affinity	 purification	 including	 the	 gradient	 of	
elution	buffer.	Samples	for	SDS‐PAGE	were	taken	from	the	supernatant	before	NiNTA	purification	(S)	and	


























The	 first	 peak	 at	 50	 ml	 corresponds	 to	 the	 void	 volume	 and	 contains	 large	 complexes	 or	
aggregates.	For	wild	type	Taspase,	the	major	peak	(blue	in	figure	3.5a)	contains	almost	exclusively	
the	proenzyme	of	full	length	Taspase	or	the	active	form	consisting	of	α‐	and	β‐subunits.	For	the	

































right	 peak	 (blue	 in	 figure	 3.6b)	 contains	 Taspase	with	 some	 impurities	 below	 20	 kDa.	 These	
proteins	were	probably	degradation	products	and	could	be	successfully	removed	by	using	a	filter	









while	 CD	 as	 well	 as	 fluorescence	 spectroscopy	 gave	 insight	 into	 the	 stabilization	 by	 sodium	
chloride.	 Possible	 posttranslational	 modifications	 could	 be	 excluded	 with	 the	 help	 of	 mass	
spectrometry,	 and	 the	 autocatalytic	 processing	 was	 followed	 by	 SDS‐PAGE	 and	 NMR	






















































The	 active	 Taspase	 (blue	 in	 figure	 3.9)	 exhibits	 two	main	 peaks	 in	 the	mass	 spectrum.	 They	
correspond	to	the	α‐subunit	(H1‐A212)	with	a	potassium	ion	as	adduct	(Δm/z	=	‐0.05	%)	and	the	
β‐subunit	(T234‐E420)	with	a	sodium	ion	as	adduct	(Δm/z	=	0.01	%).	










Mass	 spectra	 of	wild	 type	 Taspase	 (top	 panel),	 active	 Taspase	 (middle	 panel)	 and	 15N‐labeled	 inactive	









(D233A/T234A)	 in	 the	presence	of	450	mM	NaCl	on	a	Superdex	200	column	are	displayed	 in	
figure	3.10.	
Both	wild	type	Taspase	and	the	inactive	mutant	elute	in	the	range	of	a	tetramer	(90‐110	kDa;	gray	
area	 in	 figure	3.10)	 independent	of	 the	protein	 concentration.	The	expected	 range	 for	 the	αβ‐
dimer	(45‐55	kDa)	is	highlighted	in	green.	No	peak	can	be	detected	in	this	area	for	the	wild	type	



















































backbone	 peaks	 theoretically	 visible	 in	 a	 1H‐15N	HSQC	 spectrum.	However,	 only	 56	 backbone	
peaks	are	visible	in	the	1H‐15N	HSQC	spectrum.	
These	 peaks	 were	 assigned	 to	 the	 corresponding	 amino	 acids	 using	 backbone	 (HNCaCb,	











The	 spectrum	 of	 a	 Taspase	 sample	 recorded	 immediately	 after	 purification	 exhibits	 only	 22	
backbone	NH	 peaks	 (supplemental	 figure	 7.9).	 The	 other	 34	 peaks	 become	 visible	 by	 and	 by	
during	the	incubation	for	five	to	seven	days.	A	spectrum	of	a	sample	incubated	for	30	days	(data	
not	 shown)	 still	 shows	 the	 56	 peaks	 seen	 after	 seven	 days	 and	 only	 few	 signs	 of	 terminal	



































N185	and	S223.	For	 the	YASARA	model	 and	 the	 JNet	prediction,	 cylinders	 represent	helical	areas,	 lines	
represent	 random	 coil	 and	 loops	 are	 represented	 as	 curves.	 Confidence	 (conf)	 values	 range	 from	 0	
(uncertain)	to	9	(confident).	Residues	predicted	as	buried	by	sol25	and	sol0	are	labeled	(B).	Note	that	the	
N‐terminal	GP	originates	 from	the	GST	tag.	b	 In	the	proenzyme,	 the	 loop	(red	and	orange)	 is	covalently	
attached	to	the	active	site	(green).	The	model	is	based	on	the	crystal	structure	of	the	proenzyme	(PDB	2a8i).	
The	loop	amino	acids	that	are	structured	in	the	crystal	structure	of	the	proenzyme,	but	not	in	the	processed	








of	 42	 amino	 acids	 covering	 only	 the	 two	 helices	 was	 synthesized	 (CASLO	 ApS,	 Lyngby).	
Recombinant	 expression	 of	 the	 short	 fragment	 was	 considered	 ineffective,	 as	 short	 peptide	
fragments	are	typically	prone	to	degradation,	even	if	long	tags,	such	as	GST,	are	used.	












overexpressed	GST‐loop	 fusion	protein	 visible	 in	 the	 supernatant	 before	 affinity	 chromatography	 (S)	 is	
bound	to	the	column	and	thereby	removed	from	the	flow‐through	(first	lane).	After	washing,	the	GST‐loop	







additional	 proteins.	 The	 GST‐tag	was	 removed	 by	 PreScission	 protease	 treatment	 (+	 PreSc	 in	
figure	3.14a)	and	filtration	through	a	10	kDa	membrane	yielded	pure	loop	peptide	(C	in	figure	






such	 as	 positive	 ellipticity	 at	 220	 nm	 and	 a	 minimum	 at	 200	 nm.	 In	 contrast,	 the	 long	 loop	



















was	 performed	 (figure	 3.15c).	 Analysis	 of	 the	 adopted	 conformations	 over	 time	 reveals	 the	
formation	and	disorganization	of	short	helical	areas.	Most	prone	for	helix	formation	is	the	stretch	




Qualitative	assays	of	Taspase	activity	have	been	published	before	 [56,63,69].	 In	 this	 thesis,	an	
improved	assay	is	presented.	It	allowed	quantification	of	the	specific	activity	for	the	first	time	and	
















































Specific	 activity	 of	 wild	 type	 Taspase	 (wt,	 black,	 0.086	 ±	 0.0009	 µmol	 *	 min‐1	 *	 mg‐1),	 active	 Taspase	
(shortened	 loop,	 blue,	 0.063	 ±	 0.002	 µmol	 *	 min‐1	 *	 mg‐1),	 inactive	 Taspase	 (D233A/T234A	 mutant,	
0.00003	µmol	*	min‐1	*	mg‐1)	and	buffer	control	(no,	0.00006	µmol	*	min‐1	*	mg‐1)	in	the	presence	of	8	µM	





the	 activity	measured	 for	wild	 type	 Taspase.	 In	 contrast,	 the	 inactive	 Taspase	mutant	 has	 no	
catalytic	activity,	which	also	applies	to	the	buffer	control	without	Taspase.	
3.3.2 Cleavage	sequence	specificity	of	Taspase	






































































































Partial	 charges	 were	 calculated	 with	 the	 help	 of	 Chimera	 [112]	 and	 suitable	 target	 areas	 for	
docking	were	identified	by	the	sphgen	algorithm	(figure	3.22b).	The	area	covering	the	site	was	









and	 still	 cover	 a	 maximum	 of	 different	 conformations,	 chemically	 different	 molecules	 were	
selected	with	the	help	of	the	SUBSET	algorithm	[130].	Only	molecules	which	differ	from	all	other	






















The	 sample	 size	 of	 15865	 compounds	was	 large	 enough	 to	 obtain	 a	 Gaussian	 distribution	 of	
binding	scores	(figure	3.23a	and	b)	with	a	mean	binding	energy	of	26	kcal/mol	for	the	proenzyme	



















































Taspase	 activity	 is	 not	 inhibited	 in	 presence	 of	 up	 to	 1	mM	 ZINC52513265	 (figure	 3.24c)	 or	
600	µM	ZINC19323748	(figure	3.24d).	
Evaluation	 of	 the	 best	 binding	 compounds	 in	 the	 dataset	 for	 active	 Taspase	 showed	 a	 more	
heterogeneous	group	of	inhibitors	than	the	proenzyme	dataset.	A	sulfate	group	is	present	in	some	
inhibitors,	as	well,	but	an	overlay	of	the	top	inhibitors	revealed	no	striking	common	framework.	












the	 chloride	 ion	 at	 different	 positions,	 despite	 their	 close	 structural	 similarity.	 In	 the	Taspase	









Recent	 studies	 disclosed	 binding	 of	 serum	 proteins	 to	 nanoparticles	 [99].	 Furthermore,	 silica	
nanoparticles	can	inhibit	the	proteasome,	the	only	other	N‐terminal	nucleophile	(Ntn)	threonine	
protease	 (Shirley	 Knauer,	 personal	 communication).	 Hence,	 binding	 of	 Taspase	 to	 silica	
nanoparticles	 and	 their	 effect	 on	 the	 proteolytic	 activity	 was	 tested.	 Three	 different	 sizes	 of	











and	 125	nm	 (Amsil125)	 silica	 nanoparticles	 EC50	 values	 of	 35	 nM	±	 0.5	 nM	 and	10	 pM	±	 0.4	 pM	were	
obtained.	b	Fluorescence	anisotropy	titrations	with	1	µM	Atto488‐labeled	Taspase	yield	a	stoichiometry	of	
some	 10	 µmol/mg	 nanoparticles.	 This	 corresponds	 to	 roughly	 5000	 Taspase	 molecules	 per	 Amsil125	
nanoparticle	and	6	Taspase	molecules	per	Amsil8	nanoparticle.	
	




change	 in	 anisotropy	upon	binding	 for	Amsil125	 than	 for	Amsil8	due	 to	 the	higher	molecular	
weight.	 Based	 on	 these	 data,	 a	 stoichiometry	 of	 roughly	 10	 nmol	 per	 mg	 nanoparticles	 was	
calculated	for	both	Amsil8	and	Amsil125	(figure	3.27b).	This	corresponds	to	approximately	six	
Taspase	molecules	bound	per	Amsil8	nanoparticle	and	5000	Taspase	molecules	per	Amsil125	









a	 Silica	 nanoparticles	 with	 8	 nm	 (Amsil8)	 20	 nm	 (Amsil20)	 and	 125	 nm	 (Amsil125)	 diameter	 inhibit	
Taspase	activity.	EC50	values	of	41	±	9	nM,	1.4	±	0.3	nM	and	119	±	21	pM	were	calculated	for	Amsil8,	Amsil20	
and	 Amsil125,	 respectively.	 b	 Fluorescence	 anisotropy	 of	 Atto488‐labeled	 changes	 in	 the	 presence	 of	








activity	 already	 at	 low	 concentrations.	 As	 observed	 for	 binding	 to	 nanoparticles,	 the	 EC50	
concentrations	are	negatively	correlated	with	the	nanoparticle	diameter.	Hence,	Amsil125	has	the	
highest	 affinity	 with	 119	 ±	 21	 pM,	 while	 Amsil20	 and	 Amsil8	 bind	 Taspase	 at	 nanomolar	
concentrations	(EC50	=	1.4	±	0.3	nM	and	41	±	9	nM,	respectively).	
However,	 nanoparticles	 would	 artificially	 lower	 Taspase	 activity,	 if	 they	 bind	 the	 fluorescent	
substrate	and	render	it	unavailable	for	Taspase	cleavage.	To	this	end,	binding	of	the	substrate	to	
Amsil125	 nanoparticles	 was	 analyzed	 by	 fluorescence	 anisotropy	 and	 compared	 to	 Taspase	
binding	 (figure	 3.28b).	 Since	 only	 the	 anisotropy	 of	 Taspase	 changed	 in	 the	 presence	 of	
nanoparticles,	while	the	anisotropy	of	the	substrate	remained	virtually	constant,	binding	of	the	
substrate	to	nanoparticles	can	be	excluded	as	an	explanation	for	the	inhibition	of	Taspase	activity.	









EC50	 value	 of	 3	 ±	 0.8	 µM	 determined	 for	 this	 interaction	 is	 300	000‐fold	 higher	 compared	 to	
Taspase.	
To	 gain	 a	 first	 insight	 into	 the	 inhibitory	mechanism,	 the	 inhibition	 type	was	 determined	 for	
Amsil125	 by	 a	 variation	 of	 both	 substrate	 and	 nanoparticle	 concentrations	 (figure	 3.28d).	
Nonlinear	fitting	reveals	a	reversible	noncompetitive	inhibition	with	a	Ki	value	of	380	±	55	pM.	
One	 possible	 explanation	 for	 the	 observed	 inhibition	 is	 a	 destabilization	 of	 Taspase	 by	











The	 obtained	 spectra	 in	 the	 presence	 and	 absence	 of	 nanoparticles	 are	 indistinguishable,	
indicating	 that	 neither	 nanoparticle	 type	 caused	 a	 change	 in	 secondary	 structure	 content	 at	
inhibitory	 concentrations	 of	 40	 µg/ml.	 However,	 a	 change	 in	 the	 tertiary	 structure,	 such	 as	 a	
movement	or	torsion	of	a	whole	subunit,	cannot	be	excluded	by	these	data.	
Consequently,	 fluorescence	 tryptophan	 melting	 curves	 were	 recorded	 to	 get	 insight	 into	 the	
tertiary	structure,	as	well	as	the	overall	folding	state	and	stability	of	Taspase	(figure	3.29b).	As	
explicated	 in	 section	3.2.2,	Taspase	has	 a	melting	 temperature	near	56	 °C	and	77	 °C	 in	buffer	









So	 far,	 inhibition	 of	 enzyme	 activity	 could	 be	 not	 only	 restricted	 to	 Taspase,	 but	 instead	 be	 a	
general	 feature	 of	 nanoparticles.	 To	 test	 the	 hypothesis	 of	 a	 general	 inhibitory	 effect	 of	







a	 Lactate	 dehydrogenase	 (LDH)	 activity	was	 assayed	 in	 the	 presence	 of	 silica	 nanoparticles	with	 8	 nm	






















analyzed	 by	 SDS‐PAGE	 after	 limited	 proteolysis	 by	 proteinase	 K	 (figure	 3.30c).	 The	 digestion	
bands	below	both	the	full‐length	enzyme	and	the	two	subunits	indicate	that	high	concentrations	
of	proteinase	K	can	degrade	all	three	Taspase	species.	A	comparison	of	the	degradation	pattern	in	


























































were	 challenged	 with	 200	 µg/ml	 nanoparticles	 3	 hours	 after	 transfection.	 The	 presence	 of	





























Besides	 nanoparticles	 and	 compounds	 obtained	 by	 virtual	 docking,	 substrate	 analog	 Taspase	
inhibitors	 designed	 by	 Prof.	Markus	Kaiser	were	 tested	 in	 this	 project.	 Starting	 point	 for	 this	
endeavor	 was	 the	 proteolytic	 cleavage	 mechanism	 proposed	 by	 the	 Bogyo	 group	 [69].	 This	










substituted	 by	 Val	 to	 reduce	 the	 polarity.	 The	 Fmoc	 protection	 group	 was	 left	 for	 detection	 by	 UV	
absorption.	This	figure	was	taken	from	[134].	
	
The	novel	 class	of	 substrate	analog	 inhibitors	developed	 for	 this	 thesis	 features	a	 succinimide	
























Compound	 Sequence*	 IC50 [µM]	 Ki	[µM]
Comp1		 Fmoc‐Val	 >	1000	 n.d.
Comp2		 Fmoc‐Gln‐Val‐succAsp‐Gly‐Val‐Asn‐Asp‐NH2 38.7	±	12.1	 4.3	±	1.3
Comp3		 Fmoc‐Gln‐Val‐piperidineAsp‐Gly‐Val‐Asn‐Asp‐NH2 30.1	±	10.6	 3.3	±	1.2
Comp4		 Fmoc‐Gln‐Val‐allocAsp‐Gly‐Val‐Asn‐Asp‐NH2 143	±	39	 15.9	±	4.3
Comp5		 Fmoc‐Gln‐Val‐succAsp‐βAla‐Val‐Asn‐Asp‐NH2 61	±	9.5	 6.8	±	1.1
Comp6		 Fmoc‐Gln‐Val‐succGlu‐Gly‐Val‐Asn‐Asp‐NH2 14.4	±	2.8	 1.6	±	0.3
Comp7		 Fmoc‐Gln‐Val‐Asp‐Gly‐Val‐Asn‐Asp‐NH2 >	1000	 n.d.
Comp8		 Fmoc‐Gln‐Val‐isoAsp‐Gly‐Val‐Asn‐Asp‐NH2 424	±	58	 47	±	6.4
Comp9		 Fmoc‐Prg‐Bpa‐Gln‐Val‐succAsp‐Gly‐Val‐Asn‐Asp‐NH2 3.6	±	0.8	 0.4	±	0.09
Comp10		 Rhd‐Gln‐Val‐succAsp‐Gly‐Val‐Asn‐Asp‐NH2 373	±	23	 41	±	2.6
*	Fmoc:	fluorenylmethyloxycarbonyl;	succAsp:	succinimide;	piperidineAsp:	Asp	with	piperidine	protection	










could	 be	 isolated	 (Comp3).	 Although	 not	 further	 analyzed,	 this	 compound	 was	 presumably	
generated	by	an	addition	of	piperidine	to	the	succinimide	residue.	The	Ki	and	IC50	values	of	Comp3	
are	similar	to	those	of	Comp2	(Ki	=	3.3	±	1.2	µM).	Another	side	product	occurring	during	synthesis	
























replaced	by	 a	 glutarimide	 (Comp6).	This	 change	 slightly	 improved	 the	 affinity	 to	 a	Ki	 of	 1.6	±	
0.3	µM.	
The	 most	 promising	 compound	 was	 the	 photoreactive	 inhibitor	 Comp9,	 which	 possesses	 an	
additional	 N‐terminal	 benzophenone	 as	 well	 as	 a	 propargyl	 glycine	 group.	 With	 a	 Ki	 in	 the	
nanomolar	range	(0.4	±	0.09	µM)	this	compound	showed	a	tenfold	higher	inhibitory	potential	than	




















To	 verify	 the	 competitive	 type	 of	 inhibition,	 Taspase	 inhibition	by	Comp2	was	 assayed	 in	 the	
presence	of	different	substrate	concentrations	(figure	3.37a).	Nonlinear	fitting	of	the	data	with	a	



























by	 roughly	 60	%	 remained	 constant	 even	 after	 incubation	 for	 24	 hours.	However,	 the	 overall	
Taspase	activity	was	reduced	over	time	due	to	the	instability	of	Taspase	in	the	assay	buffer	(see	
section	3.2.2).	


















respectively.	 This	 indicates	 that	 the	 inhibitor	 binds	 to	 the	 α‐subunit	 of	 Taspase,	 while	 no	
interaction	with	 the	 β‐subunit	 is	 visible.	 Furthermore,	 no	 interaction	 above	 background	with	













to	enter	 the	 cell,	 their	 ability	 to	 cross	 the	 cell	membrane	was	 tested.	 For	 this,	Hela	 cells	were	
treated	with	the	fluorescent	compound	Comp10.	After	defined	incubation	times,	the	cells	were	









































case	of	 a	 t(4;11)	 translocation,	Taspase	 is	 the	key	enzyme	 for	 the	proteolytic	activation	of	 the	
oncogenic	 MLL	 protein.	 Consequently,	 inhibition	 of	 Taspase	 could	 prevent	 the	 malignant	
transformation	of	cells	with	t(4;11)	translocation	and	probably	also	solid	tumors.	
For	the	development	of	new	inhibitors,	a	detailed	understanding	of	the	biochemical	properties,	
the	 catalytic	 mechanism	 and	 the	 structure	 of	 the	 target	 enzyme	 are	 of	 tremendous	 value.	
Therefore,	 Taspase	 was	 subjected	 to	 extensive	 biochemical	 characterization	 with	 respect	 to	




















cleavage	were	quantified	 for	 the	 first	 time	(0.03	and	0.08	s‐1,	 respectively)	and	are	rather	 low	
compared	 to	 other	 asparaginases,	 for	 example	 from	 the	 enterobacterial	 Pectobactrium	



















cleavage	 is	 below	 1:500,	 which	 is	 more	 than	 two	 orders	 of	 magnitude	 more	 efficient	 than	
published	 [71].	 One	 plausible	 explanation	 that	 the	 catalytic	 activity	 in	 vitro	 is	 higher	 than	
published	 before	 refers	 to	 the	 instability	 of	 Taspase	 in	 the	 assay	 buffer.	 In	 this	 regard,	 the	
requirement	 of	 salt	 for	 stability	 was	 pinpointed	 (figure	 3.8)	 and	 NaCl	 concentrations	 below	








While	 the	 general	 principle	 of	 autocatalytic	 processing	 of	 a	 proenzyme	 is	 shared	 among	
asparaginases,	 the	 kinetics	 of	 the	 activation	 rates	 varies	 significantly	 between	 different	
asparaginases	(table	4.1).	For	instance,	activation	of	E.	coli	asparaginase	takes	less	than	one	day	
[62],	contrary	to	the	fivefold	slower	activation	of	Flavobacterium	meningosepticum	asparaginase	









Taspase	 100	%	 0	Å dimer dimer 3	days
Asparaginase	 36	%	 0.9	Å dimer dimer	+	monomer	 90	days
F.	m.	Glycoamidase	 27	%	 1.1	Å dimer monomer <	5	days
E.	c.	Asparaginase	 21	%	 1.5	Å dimer dimer <	1	days
Proteasome	 14	%	 4.7	Å heptamer heptamer α‐SU‐dependent
	
	
A	detailed	study	of	 the	autocatalytic	process	provided	 for	 the	 first	 time	 information	about	 the	
























With	 this	 technique,	 the	 activation	 can	 be	 followed	more	 detailed	 than	with	 SDS‐PAGE	 at	 the	
atomic	 level.	 The	 NMR	 peak	 intensities	 of	 the	 amino	 acids	 in	 the	 fragment	 released	 by	 the	
autocatalytic	activation	event	(referred	to	as	Taspase	loop)	increased	over	time	(supplemental	
figure	 7.9).	 Since	 the	 assigned	 peaks	 in	 the	 1H‐15N‐HSQC	 spectrum	 of	 Taspase	 correspond	 to	
flexible	 loop	 regions	 and	 disordered	 regions	 (see	 section	 4.1.4	 for	 detailed	 explanation),	 the	
appearance	of	peaks	correlates	with	an	 increased	 flexibility	of	 the	corresponding	amino	acids.	




SDS‐PAGE‐based	 analysis	 of	 the	 autocatalytic	 activation,	 the	 NMR	 experiments	 indicate	 a	
somewhat	 slower	 activation	 rate.	 This	 difference	 can	 presumably	 be	 attributed	 to	 the	 lower	









After	 autoproteolysis,	 the	 subunits	of	 asparaginase	 type	 II	 family	proteins	 assemble	 to	 an	αβ‐
heterodimer.	 In	 Taspase,	 the	 αβ‐heterodimer	 displays	 a	 remarkably	 high	 stability.	 This	 high	
























indicated	 only	 a	 low	 affinity	 of	 the	 two	 αβ‐heterodimers	 in	 solution	 [68].	 Nevertheless,	 these	
contradictory	 experiments	 can	 be	 brought	 in	 line	 by	 a	 consideration	 of	 the	 Taspase	





































residues)	 or	 the	 Taspase	 loop	 (12	 residues),	 while	 the	 rigid	 parts	 with	 a	 defined	 secondary	
structure	 remain	 invisible.	Hence,	 the	missing	 regions	 of	 the	Taspase	 crystal	 structure	 can	be	
selectively	investigated	by	NMR	spectroscopy.	An	important	factor	for	the	signal	intensity	in	NMR	
spectroscopy	is	the	rotation	correlation	time	of	the	protein,	which	correlates	with	the	protein	size.	
This	 rotational	 correlation	 time	 is	 related	 to	 both	 the	 longitudinal	 (T1)	 and	 transversal	 (T2)	
relaxation	times.	Large	proteins	like	Taspase	exhibit	long	T1	and	short	T2	times,	which	results	in	
line‐broadening	in	the	resultant	NMR	spectrum	due	to	a	loss	of	magnetization	and	renders	the	
peaks	 invisible.	 However,	 the	 large	 loop	 regions	 of	 Taspase	 obviously	 behave	 like	 separate	





















a	 The	 proposed	 structure	 is	 based	 on	 NMR	 and	 CD	 spectroscopy	 data	 as	 well	 as	 secondary	 structure	
prediction.	The	model	shows	a	helix‐turn‐helix	motif.	NLS	amino	acids	are	highlighted	in	orange,	critical	
NLS	residues	are	displayed	 in	red.	The	overlay	of	 two	possible	conformations	 indicates	 flexibility	of	 the	
termini.	b	Location	of	the	loop	in	the	Taspase	protein	(PDB	2a8j).	
	






the	 catalytic	 site	 that	 is	 disordered	 in	 the	 crystal	 structures	 of	 human	 glycosylasparaginase,	
human	 asparaginase,	 plant	 asparaginase,	 E.	 coli	 asparaginase,	 and	 F.	 meningosepticum	
glycosylasparaginase.	Sequence‐based	models	of	the	loop	for	these	Taspase	homologs	(figure	4.4)	
reveal	that	only	the	Taspase	loop	is	predicted	to	be	predominantly	helical.	In	contrast,	the	other	
loops	 are	 predicted	 as	 pure	 random	 coil	 (human	 asparaginase,	 E.	 c.	 asparaginase,	 and	 F.	m.	









Modeled	structures	of	 the	Taspase	 loop	homologous	regions	 in	other	 type	 II	asparaginases.	The	 loop	of	
human	Taspase	(template	PDB	2a8i;	 loop	 length:	25	aa)	 is	predicted	as	predominantly	helical,	while	 for	
human	glycosylasparaginase	(template	PDB	1apy;	loop	length:	20	aa),	human	asparaginase	(template	PDB	
4pvs;	 loop	 length:	 14	 aa),	 plant	 asparaginase	 (template	 PDB	 2gez;	 loop	 length:	 33	 aa),	Escherichia	 coli	




Although	 loops	 shorter	 than	 the	 25	 amino	 acids	 Taspase	 loop	 are	 unstructured	 (F.	 m.	



















leukemic	 cells.	 Consequently,	 depletion	 of	 asparagine	 by	 asparaginase	 leads	 to	 inhibition	 of	
protein	 synthesis	 and	 subsequent	 cell	 death	 [144].	 Thus,	 asparaginase	 is	 successfully	 used	 as	




substrate	 specificity	 and	 the	 catalytic	 mechanism.	 This	 is	 assumed	 to	 be	 the	 reason,	 why	
commercial	 protease	 inhibitors,	 such	as	 the	 serine	protease	 inhibitor	PMSF	or	 the	 cOmplete™	




However,	 this	 compound	 is	 not	 specific	 for	 Taspase	 and	 was	 initially	 identified	 as	 an	 anti‐
angiogenic	 drug.	 Besides	 the	 toxicity	 of	 the	 arsenic	 moiety,	 this	 compound	 has	 been	 under	
discussion,	 since	 inhibition	 could	 not	 be	 reproduced	 in	 a	 cellular	 assay	 [133].	 This	 lack	 of	
inhibition	by	NSC48300	was	here	confirmed	in	vitro	(figure	3.21),	which	questions	the	potential	
of	the	compound	even	more.	












sulfone	and	vinyl	ketone	derivatives	 [69].	Despite	 the	moderate	 inhibitory	potential	 (IC50	near	
30	µM	for	the	best	compound	yzm18),	these	studies	proved	helpful	for	the	design	of	new	substrate	
analog	 compounds.	 These	 succinimide	 peptides	 tested	 in	 this	 thesis	 are	 discussed	 separately	
below	(section	4.3).	
Enforced	dimerization	by	the	fusion	of	Jun‐	and	Fos‐tags	to	the	C‐terminus	of	Taspase	resulted	
in	 a	 loss	 of	 catalytic	 activity	 [68].	 This	 finding	 seems	 to	be	 in	 contrast	 to	 the	 catalytic	 activity	








C‐termini	 of	 the	 natural	 dimer	 are	more	 than	 60	Å	 apart	 on	 the	 opposite	 ends	 of	 the	 hetero‐
tetramer	(figure	7.20).	In	the	enforced	dimer,	a	steric	hindrance	could	therefore	prevent	substrate	
binding	 and	 thus	 abolish	 catalytic	 activity.	 Furthermore,	 the	 artificial	 generation	 of	 higher	
oligomeric	Taspase	species	by	Jun/Fos	mediated	dimerization	was	not	excluded,	which	might	be	
another	reason	for	the	missing	activity.	
Molecular	plugs	 are	 a	 comparatively	 new	mechanism	 to	 occlude	 the	 active	 site	 by	 artificial	
ligands.	 The	 Schmuck	 group	 achieved	 an	 inhibition	 of	 the	 serine	 protease	 β‐tryptase	 with	
nanomolar	Ki	using	a	four‐armed	ligand	to	block	the	active	site	noncompetitively	[146,147].	This	
approach	 could	 also	 be	 applicable	 to	 Taspase,	 if	 the	 compounds	 sterically	 prevent	 substrate	
binding.	Consequently,	41	of	these	molecular	plug	derivatives	were	obtained	from	the	Schmuck	
group	 and	 tested	 for	 Taspase	 inhibition.	 Although	 these	 compounds	 covered	 combinations	 of	




Owing	 to	 their	high	 surface	 to	volume	ratio,	nanoparticles	possess	a	high	 free	 surface	energy,	










understand	 why	 some	 proteins	 bind	 to	 nanoparticles,	 while	 others	 are	 rejected,	 the	 protein‐
nanoparticle	 interface	 needs	 to	 be	 examined	 in	 more	 detail.	 However,	 the	 interactions	 of	
nanoparticles	with	biomolecules	are	still	not	fully	elucidated,	despite	extensive	research	in	recent	
years.	Nevertheless,	 some	concepts	 emerged	 from	 these	efforts,	which	help	 to	understand	 the	

















for	each	 type	of	nanoparticle	and	establishes	 rapidly.	Hence,	nanoparticles	 interact	 selectively	
with	only	some	proteins	and	do	not	bind	every	protein	[99,150].	This	is	in	agreement	with	the	
binding	of	Taspase	to	silica	nanoparticles,	while	parvalbumin	is	rejected	(section	3.5.1).	
For	 the	 interaction	of	Taspase	with	negatively	charged	amorphous	silica	particles	 (Amsil),	 the	
surface	area	and	curvature	 showed	a	great	 influence	on	Taspase	binding	affinity	and	 capacity	
(figure	 3.27).	 The	EC50	 of	 nanoparticles	with	125	nm	diameter	 (Amsil125)	 is	 3500‐fold	 lower	











3.27	and	 figure	3.28),	 indicating	 that	every	Taspase	molecule	bound	 to	nanoparticles	 loses	 its	
activity.	However,	the	inhibition	of	enzymes	by	nanoparticles	is	poorly	investigated	and	scarcely	
described.	One	example	is	the	inhibition	of	chymotrypsin	multi‐walled	carbon	nanotubes,	which	






carbon	 nanotubes	 on	 soybean	 peroxidase	 and	 chymotrypsin	 activity	 [109].	 They	 found	 an	
irreversible	 inhibition	 of	 chymotrypsin	 activity	 and	 more	 than	 90	 %	 inhibition	 of	 soybean	
peroxidase	 activity.	 For	 the	 inhibition	 mechanism	 of	 chymotrypsin,	 the	 authors	 suggested	 a	
denaturation	of	 the	protein,	while	 the	 inhibitory	mechanism	for	soybean	peroxidase	remained	







after	 binding	 as	 hetero‐tetramer	 or	 dimer,	 separation	 of	 the	 subunits,	 as	 well	 as	 structural	 or	
conformational	changes,	crowding	effects,	fibrillation	and	oxidation.	Modified	according	to	[92].	
	










the	nanoparticle	 and	 the	protein	 investigated.	 For	 instance,	 soybean	peroxidase	and	 subtilisin	
Carlsberg	 were	 stabilized	 by	 spherical	 nanoparticles	 such	 as	 C60	 fullerenes,	 silica	 or	 gold	
nanoparticles	 [155],	 while	 chymotrypsin	 unfolds	 upon	 binding	 to	 carbon	 nanotubes	 [109].	
Additionally,	the	storage	stability	of	glucose	oxidase	was	significantly	increased	after	binding	to	











to	be	 important	 for	 inhibition	 for	example	 in	 the	case	of	catalase	 [159].	However,	oxidation	of	
Taspase	is	unlikely	due	to	the	highly	reducing	milieu	in	the	buffer	containing	10	mM	DTT.	
Moreover,	 binding	 of	 proteins	 to	 nanoparticles	 can	 greatly	 increase	 the	 local	 protein	
concentration	in	the	nanoparticle	corona	and	cause	layering	or	crowding	effects,	which	are	known	
to	promote	aggregation	[160,161].	Indeed,	the	stoichiometry	of	6	and	5000	Taspase	molecules	per	
Amsil8	 and	 Amsil125	 nanoparticle	 (figure	 3.27b),	 respectively,	 indicate	 high	 local	 Taspase	

























This	 either	 results	 in	 noncompetitive	 inhibition	 (figure	 3.28)	 that	 is	 either	 allostery‐like	 or	
occludes	the	active	site.	However,	the	latter	mechanism	is	more	likely,	since	the	positively	charged	










Importantly,	 control	 experiments	with	 lactate	dehydrogenase,	 chymotrypsin	 and	proteinase	K	
showed	no	 or	 low	 inhibition	 of	 the	 respective	 enzyme	 activity	 at	 nanoparticle	 concentrations	














compete	 for	 binding.	 To	 test	 Taspase	 binding	 under	 such	 conditions,	 Hela	 cell	 lysates	 with	
overexpressed	 GFP‐Taspase	 were	 tested	 for	 Taspase	 activity	 in	 the	 presence	 of	 silica	
nanoparticles.	
While	nanoparticles	were	able	to	inhibit	Taspase	by	up	to	90	%	in	vitro,	the	maximum	inhibitory	
effect	 is	 limited	 to	50	%	 in	cell	 lysates	 (figure	3.31).	Consequently,	 the	nanoparticle	 surface	 is	
probably	partly	occupied	by	other	cellular	proteins,	which	reduce	the	inhibitory	potential	with	






Owing	 to	 their	 large	 size,	 nanoparticles	 cannot	 enter	 the	 cell	 passively,	 but	must	 be	 taken	up	
actively	by	the	cell.	However,	the	efficiency	of	this	cellular	uptake	again	depends	on	size	and	shape	









were	 tested	 for	 cytotoxicity	 against	 human	 immune	 cells	 and	 monocytes	 were	 found	 to	 be	
particularly	 susceptible	 to	 the	 reactive	 oxygen	 species	 induced	 by	 the	 nanoparticles	 [165].	
Especially	 crystalline	 silica	 (SiO2)	 is	 known	 to	 induce	 chronic	 inflammation,	 fibrosis	 and	 lung	
cancer	 upon	 inhalation	 [166,167].	 In	 stark	 contrast	 to	 the	 high	 toxicity	 of	 crystalline	 silica,	
amorphous	 silica	 nanoparticles	 are	 regarded	 to	 be	 safe	without	 displaying	 chronic	 effects,	 as	
studied	 in	 rats	 [168].	 This	 is	 in	 agreement	 with	 the	 good	 viability	 of	 the	 cells	 after	 Amsil	
nanoparticle	challenge	with	normal	proliferation,	cell	size	and	morphology	(figure	3.33).	
Using	 fluorescently	 labeled	 nanoparticles,	 Tenzer	 and	 colleagues	 cold	 confirm	 that	 the	 silica	
nanoparticles	used	in	this	project	are	readily	taken	up	within	roughly	one	hour	[99].	Furthermore,	




importin‐α/nucleophosmin‐dependent	 manner	 [74].	 Importantly,	 the	 nuclear	 localization	 is	



















Altogether,	 the	 inhibition	 of	 Taspase	 by	 silica	 nanoparticles	 at	 nanomolar	 concentrations	
highlights	for	the	first	time	that	nanoparticles	are	able	to	qualitatively	inhibit	enzymes	in	vivo,	and	









targeted	 the	 S‐site,	 but	 not	 the	 S’‐site	 and	displayed	 only	moderate	 inhibition	 (IC50	 =	 30	µM).	





(figure	 1.9;	 [69]).	 Concerning	 the	 high	 structural	 similarity	 of	 Taspase	 with	 other	 type	 II	
asparaginases	[66,139],	the	catalytic	mechanism	is	likely	to	show	some	similarities.	Nevertheless,	
asparaginases	hydrolyze	the	asparagine	side	chain,	while	Taspase	is	an	endopeptidase.	However,	
if	 the	 substrate	 undergoes	 a	 rearrangement	 via	 a	 succinimide‐hydrate	 intermediate,	 Taspase	
could	cleave	the	 isopeptide	bond	at	 the	asparagine	side	chain	(figure	1.9),	which	 is	again	very	





these	 experimental	 data.	 Indeed,	 these	 data	 strongly	 support	 the	 previously	 hypothesized	




































The	 inhibition	 type	 of	 the	 newly	 designed	 peptidyl‐succinimide	 inhibitors	 is	 expected	 to	 be	
competitive,	as	this	is	usually	seen	for	substrate	analog	compounds.	Indeed,	the	substrate	could	
replace	the	inhibitor	(figure	3.36b).	Furthermore,	binding	of	the	inhibitor	to	Taspase	in	absence	
of	 the	 substrate	 was	 verified	 by	 microscale	 thermophoresis	 (figure	 3.36a)	 and	 excludes	
uncompetitive	 inhibition	 (i.e.	 binding	of	 the	 enzyme‐substrate	 complex).	Moreover,	 prolonged	
incubation	 times	 of	 enzyme	 and	 inhibitor	 did	 not	 result	 in	 increased	 inhibition,	 hinting	 at	 a	
reversible	 nature	 of	 the	 inhibition.	 However,	 unlike	 allosteric	 inhibitors,	 substrate	 analog	
protease	 inhibitors	are	prone	 to	cleavage	due	 to	 their	high	structural	 similarity	 to	 the	natural	
substrate.	In	the	case	of	Taspase,	a	degradation	of	the	succinimide	motif	could	be	ruled	out	and	
the	 inhibitory	 potential	 remained	 constant	 over	 time	 (figure	 3.37).	 Moreover,	 an	 artificial	










inhibition	 (Ki	=	6.8	±	1.1	µM),	which	pinpoints	 the	 importance	of	 the	S’‐site	 for	 tight	 inhibitor	
binding.	
Moreover,	derivatization	of	the	inhibitory	succinimide	motif	showed	that	an	extension	of	the	5‐









Despite	 its	 promising	 inhibitory	 effect	 in	 vitro,	 the	 inhibitory	 effect	 in	 cell	 lysates	 with	
overexpressed	 GFP‐Taspase	 was	 30‐fold	 lower	 (IC50	 =	 111	 µM).	 Regarding	 this,	 the	 chloride	
concentration	of	150	mM	NaCl	in	the	lysis	buffer	is	to	be	considered,	which	was	not	present	in	the	


































with	 the	 proenzyme,	 or	 more	 likely	 an	 interaction	 with	 the	 SDS‐resistant	 αβ‐dimer	 (see	

















logP	 ‐0.4	to	5.6a	 2.83 ±	0.97c
Mw	 160	to	480	Daa	 1296 Da
Molar	refractivity	 40	to	130a	 333c
Number	of	atoms	 20	to	70a	 168





the	 succinimide	 compounds.	 Unexpectedly,	 the	 compound	 was	 indeed	 able	 to	 cross	 the	 cell	
membrane	and	was	found	evenly	distributed	in	the	cells	after	5	hours	(figure	3.39c).	Importantly,	
the	 uptake	was	more	 than	 twofold	 higher	 if	 the	 cells	 were	 incubated	 in	 serum‐free	medium.	













affinity	 of	 the	 inhibitor,	 as	 explicated	 above.	 Moreover,	 degradation	 or	 modification	 of	 the	













bioinformatics	 approach	 did	 not	 yield	 active	 compounds,	 silica	 nanoparticles	 were	 found	 to	
inhibit	 Taspase	 noncompetitively.	 However,	 the	 most	 promising	 compounds	 were	 substrate	
analog	peptides	 containing	 a	 succinimide	moiety,	 because	 it	 is	 not	 expected	 that	 selectivity	 is	
achievable	 for	 uncoated	 nanoparticles	 by	 rational	 design	 with	 the	 current	 knowledge.	 These	
compounds	exhibited	good	inhibitory	potential	in	vitro,	while	the	in	vivo	potential	was	rather	low.	
Hence,	these	compounds	might	be	improved	to	achieve	higher	stability	and	better	bioavailability.	
Primarily,	 better	 bioavailability	 requires	 a	 reduction	 of	 the	 molecular	 weight	 and	 increased	
hydrophobicity	[172,177].	To	this	end,	the	molecular	weight	can	be	reduced	by	roughly	15	%	by	
removing	 the	N‐terminal	 Fmoc	 group,	which	was	 shown	 to	 be	 irrelevant	 for	 binding.	 Cellular	
experiments	to	elucidate	the	Taspase	consensus	sequence	revealed	that	the	presence	of	only	one	
of	the	two	aspartates	at	P3’	and	P4’	is	sufficient	for	cleavage	[70].	Consequently,	the	peptide	part	
of	 the	 inhibitor	 could	be	 shortened	by	 the	C‐terminal	 aspartate	at	P4’,	 if	 the	P3’	 asparagine	 is	



















of	 peptidic	 ligands.	 For	 example,	 methylation,	 methoxy	 or	 benzyl	 ether	 modifications	 greatly	

















its	 implication	 in	 leukemias	and	solid	 tumors.	Although	Taspase	 is	not	an	oncogene	 itself,	 it	 is	
crucially	 required	 for	 the	 proteolytic	 activation	 of	 the	 MLL	 oncogene	 as	 well	 as	 MLL	 fusion	
proteins	generated	by	chromosomal	translocations.	Hence,	MLL‐dependent	cells	can	successfully	
be	 targeted	 by	 inhibition	 of	 Taspase	 activity.	However,	 Taspase	 is	 insensitive	 to	 inhibition	 by	
general	 serine,	 cysteine	 or	 metalloprotease	 inhibitors.	 Furthermore,	 the	 limited	 number	 of	
available	Taspase	 inhibitors	display	 either	 low	 inhibitory	potential	 or	 broad	bioactivity.	 Thus,	
novel	Taspase	inhibitors	are	still	urgently	required.	
In	a	first	step,	detailed	characterization	revealed	for	the	first	time	that	recombinant	Taspase	and	
protein	 overexpressed	 in	 eukaryotic	 cells	 are	 comparable	 with	 respect	 to	 their	 catalytic	
parameters.	
Moreover,	the	specific	catalytic	activity	(0.03	U/mg)	was	determined,	as	well	as	a	20‐fold	higher	
efficiency	 regarding	 cleavage	 of	 the	 CS2	 cleavage	 site	 of	 MLL	 over	 CS1.	 Regarding	 stability,	
Taspase	 rapidly	 loses	 its	 catalytic	 activity	 (half‐life	 <	 3	 h),	 unless	 it	 is	 stabilized	 by	 high	
concentrations	of	NaCl	(≥	450	mM).	Additionally,	the	autocatalytic	processing	event	required	for	








were	 discovered	 as	 novel	 Taspase	 inhibitors.	 In	 fact,	 silica	 nanoparticles	 are	 known	 to	 bind	
proteins,	 albeit	 nanoparticle‐mediated	 inhibition	 of	 enzyme	 activity	 is	 scarcely	 described.	






















Die	 Threonin‐Protease	 Taspase1	 stellt	 aufgrund	 ihrer	 Beteiligung	 an	 Leukämien	 und	 soliden	
Tumoren	einen	wichtigen	neuen	Ansatzpunkt	für	Krebsmedikamente	dar.	Obwohl	Taspase	selbst	
kein	Onkogen	ist,	ist	sie	unabdingbar	für	die	proteolytische	Aktivierung	des	Onkogens	MLL	und	
der	 durch	 Translokationen	 entstandenen	 MLL‐Fusionsproteine.	 Deshalb	 reagieren	 MLL‐
abhängige	Zellen	besonders	sensitiv	auf	Taspase‐Inhibition.	Allerdings	sind	sämtliche	allgemei‐
nen	Serin‐,	 Cystein‐	 und	Metalloprotease‐Inhibitoren	unwirksam	gegen	Taspase,	 und	 auch	die	
wenigen	 verfügbaren	 Taspase‐Inhibitoren	 besitzen	 entweder	 nur	 geringes	 Inhibitorpotential	
oder	 ein	breites	Wirkspektrum.	Daher	 sind	neue	Taspase‐Inhibitoren	nach	wie	vor	von	hoher	
Relevanz.	








und	 Aspartat	 233	 ist	 in	 der	 Kristallstruktur	 ungeordnet,	 konnte	 aber	 dank	 NMR‐	 und	 CD‐
Spektroskopie	 als	 potentielles	 Helix‐Turn‐Helix‐Motiv	 identifiziert	 werden.	 Des	 Weiteren	
belegten	analytische	Gelfiltrationen	die	Aktivität	von	Taspase	als	Hetero‐Tetramer.	Mithilfe	dieser	
Informationen	wurde	ein	in	vitro	Assay	optimiert	und	für	Inhibitortests	verwendet.	
Während	 der	 kontrovers	 diskutierte	 Inhibitor	 NSC48300	 und	 die	 mittels	 virtuellen	 Dockings	
ermittelten	 Substanzen	 keine	 Inhibition	 zeigten,	 konnten	 Silikatnanopartikel	 und	 Succinimid‐
Peptide	 als	 neue	 Taspase‐Inhibitoren	 identifiziert	 werden.	 Obwohl	 Proteinbindung	 an	
Nanopartikel	 bekannt	 ist,	 ist	 eine	durch	diese	 vermittelte	Enzyminhibition	kaum	beschrieben.	
Umso	überraschender	sind	die	IC50‐Werte	im	nano‐	und	picomolaren	Bereich,	die	sowohl	in	vitro	
als	auch	in	Zellen	beobachtet	wurden.	Weiterhin	konnte	mit	verschiedenen	Nanopartikelgrößen	
eine	 positive	 Korrelation	 von	 Durchmesser	 und	 Affinität	 belegt	 werden.	 Weitere	 Analysen	
ergaben	 eine	 nichtkompetitive	 Inhibition	 und	 keine	 Strukturänderung	 bei	 Bindung.	





beste	 Verbindung	 zeigte	 einen	Ki‐Wert	 von	 400	 ±	 88	nM	und	 ist	 damit	 ein	 zehnfach	besserer	
Hemmstoff	 als	 der	 beste	 zuvor	 beschriebene	 Taspase‐Inhibitor.	 Des	 Weiteren	 konnte	 die	




















p1	 7.8239	 20.86	µs	 1H	90°	high	power	pulse
p3	 40.617	 18	µs	 13C	90°	high	power	pulse
p21	 89.492	 35.5	µs	 15N	90°	high	power	pulse
pcpd1	 0.17596	 50	µs	 1H	DIPSI‐2	decoupling
pcpd2	 3.6535	 60	µs	 13C	decoupling	
pcpd3	 4.352	 180	µs	 15N	GARP	decoupling	
sp1	 0.00039212 	 1H	90°	shaped	pulse	for	H2O	on	resonance	
sp2	 53.544	 	 13C	90°	shaped	pulse	for	Cali on	resonance	
sp3	 47.381	 	 13C	180°	shaped	pulse	for	Cali on	resonance	
sp5	 47.381	 	 13C	180°	shaped	pulse	for	C=O	off	resonance	
sp8	 53.544	 	 1H	90°	shaped	pulse	for	time	reversed	pulse	
d1	 	 2	s	 relaxation	delay


























hsqcetf3gpsi2	 15N	 40	 115	 256	 DQD	 1H	 16.08 4.	695	 1024	 E‐AE	 ‐	 ‐	 ‐	 ‐	 ‐	
sofast‐HMQC	
sfhmqcf3gpph	 15N	 34	 115	 200	 DQD	 1H	 15	 4.	695	 1024	 STPPI ‐	 ‐	 ‐	 ‐	 ‐	
15N‐TOCSY‐HSQC	
dipsihsqc3gpsi3d	
1H	 15.94	 4.695	 128	 STPPI 15N	 39	 119	 48	 STPPI 1H	 16	 4.696	 2048	 DQD	
HNCACB	
hncacbgpwg3d	
13C	 80	 39	 128	 STPPI 15N	 34	 119	 40	 STPPI 1H	 15	 4.696	 2048	 DQD	
CBCACONH	
cbcaconhgpwg3d	
13C	 75	 39	 128	 STPPI 15N	 34	 119	 36	 STPPI 1H	 15	 4.696	 2048	 DQD	
HBHANH	
hbhanhgpwg3d	
1H	 15	 4.695	 128	 STPPI 15N	 34	 119	 40	 STPPI 1H	 8	 4.695	 2048	 DQD	
HBHACONH	
hbhaconhgpwg3d	
1H	 15	 4.695	 128	 STPPI 15N	 34	 119	 40	 STPPI 1H	 8	 4.695	 2048	 DQD	
HCCH‐TOCSY	
hcchdigp3d	
1H	 8	 4.695	 128	 STPPI 13C	 75	 39	 64	 STPPI 1H	 16	 4.695	 2048	 DQD	
HNCA	
hncagpwg3d	












[ppm]	 MC2*	 REV	 WDW	 nuc	
SI	
[ppm] MC2*	 REV	 WDW nuc	
SI	
[ppm]	 MC2*	 REV	 WDW
15N‐HSQC	 15N	 2048	 E‐AE	 False	 Qsine	 1H	 4096	 ‐	 False	 Qsine	 ‐	 ‐	 ‐	 ‐	 ‐	
sofast‐HMQC	 15N	 1024	 STPPI	 False	 Qsine	 1H	 2048	 ‐	 False	 Qsine	 ‐	 ‐	 ‐	 ‐	 ‐	
15N‐TOCSY‐HSQC	 1H	 256	 STPPI	 False	 Qsine	 15N	 128	 E‐AE	 False	 Qsine	 1H	 1024	 ‐	 False	 Qsine	
HNCACB	 13C	 256	 STPPI	 False	 Qsine	 15N	 128	 STPPI True	 Qsine	 1H	 2048	 ‐	 False	 Qsine	
HBHACONH	 13C	 256	 STPPI	 False	 Qsine	 15N	 64	 STPPI True	 Qsine	 1H	 2048	 ‐	 False	 Qsine	
HBHANH	 1H	 256	 STPPI	 False	 Qsine	 15N	 128	 STPPI True	 Qsine	 1H	 2048	 ‐	 False	 Qsine	
HBHACONH	 1H	 128	 STPPI	 False	 Qsine	 15N	 64	 STPPI True	 Qsine	 1H	 2048	 ‐	 False	 Qsine	
HCCH‐TOCSY	 1H	 512	 STPPI	 False	 Qsine	 13C	 256	 STPPI False	 Qsine	 1H	 2048	 ‐	 False	 Qsine	
























a	Map	 of	 the	 pC3	 vector	 containing	wild	 type	 Taspase	with	 C‐terminal	 eGFP.	b	Map	 of	 the	 pC3	 vector	
containing	inactive	Taspase	(T234V)	with	C‐terminal	BFP.	c	Map	of	the	pC3	vector	containing	the	reporter	
substrate	 (BioTasp)	used	 for	 the	cellular	Taspase	activity	assay.	The	coded	protein	comprises	a	nuclear	











The	Taspase	 loop	was	 amplified	 from	 the	 plasmid	 for	wild	 type	Taspase	 (top	 left	 panel)	 by	 PCR	 using	
primers	with	binding	sites	indicated	in	purple.	The	target	vector	(top	right	panel)	was	digested	with	ApaI	










Purification	 of	 inactive	 Taspase	 was	 performed	 as	 described	 for	 wild	 type	 Taspase	 (section	 3.1.3).	
a	Chromatogram	of	the	NiNTA	column	elution.	The	fractions	highlighted	in	blue	were	used	for	gel	filtration,	
while	 the	 fractions	 highlighted	 in	 green	 were	 purified	 again	 by	 NiNTA	 affinity	 chromatography.	 b	
Chromatogram	 of	 the	 NiNTA	 affinity	 chromatography	 of	 the	 peak	 highlighted	 green	 in	 (a).	 Fractions	








As	 the	 first	elution	peak	after	NiNTA	affinity	chromatography	contained	a	significant	amount	of	 impure	
Taspase	(section	3.1.3),	the	peak	fractions	were	diluted	to	reduce	the	imidazole	concentration	to	10	mM	
and	again	applied	to	a	NiNTA	column.	All	parameters	were	taken	from	the	first	purification,	described	in	
section	 3.1.3.	 a	 Chromatogram	 of	 the	 NiNTA	 column	 elution.	 The	 fractions	 highlighted	 in	 blue	 were	




























































aa	 Res	 HN	 N	 Cα	 Cβ	 Hα	 Hβ	 Hγ	 Hδ	 Hε	
9	 Ser	 8.379	±	0.004	 117.112	±	0.142	 58.552	±	0.096 64.041	±	0.199	 4.499	±	0.005	 3.894	±	0.029	 ‐	 ‐	 ‐	
10	 Gly	 8.382	±	0.006	 110.706	±	0.097	 45.332	±	0.078 ‐	 3.95	±	0.017	 ‐	 ‐	 ‐	 ‐	
11	 Glu	 8.223	±	0.005	 120.5	±	0.049	 56.763	±	0.055 30.194	±	0.015	 4.259	±	0.007	 1.997	±	0.017	 2.197	±	0.042	 	 	
12	 Gly	 8.386	±	0.003	 109.791	±	0.086	 45.18	±	0.011 ‐	 3.914	±	0.02	 ‐	 ‐	 ‐	 ‐	
13	 Leu	 7.994	±	0.005	 122.667	±	0.032	 53.124	±	0.028 41.668	 4.599	±	0.011	 1.594	±	0.009	 1.533	 0.896	±	0.002	 ‐	
23	 Gly	 8.263	±	0.005	 107.765	±	0.036	 45.327	±	0.005 ‐	 3.912	±	0.011	 ‐	 ‐	 ‐	 ‐	
24	 Lys	 8.02	±	0.004	 120.824	±	0.055	 56.274	±	0.054 33.037	±	0.083	 4.305	 1.72	±	0.01	 1.382	 ‐	 3.006	
25	 Ile	 8.15	±	0.006	 122.453	±	0.08	 61.219	±	0.057 38.712	±	0.114	 4.206	±	0.002	 1.831	±	0.027	 1.258	/	1.463	 ‐	 ‐	
26	 Thr	 8.2	±	0.004	 118.662	±	0.061	 61.838	±	0.079 70.13	±	0.084	 4.32	±	0.012	 ‐	 ‐	 1.164	 ‐	
27	 Ala	 8.287	±	0.005	 126.192	±	0.059	 52.94	±	0.091 19.053	±	0.094	 4.238	±	0.027	 1.36	±	0.019	 ‐	 ‐	 ‐	
28	 Lys	 8.187	±	0.003	 120.311	±	0.069	 ‐	 ‐	 4.21	±	0.015	 1.716	±	0.022	 ‐	 ‐	 ‐	
32	 Thr	 8.06	±	0.003	 115.009	±	0.064	 62.212	±	0.055 69.791	±	0.074	 4.265	±	0.008	 	 1.091	 ‐	 ‐	
33	 Lys	 8.219	±	0.004	 123.407	±	0.104	 56.576	±	0.081 32.539	 4.259	 1.741	±	0.007	 	 ‐	 ‐	
34	 Gln	 8.331	±	0.003	 121.675	±	0.047	 56.822	±	0.08 30.11	±	0.13	 4.214	±	0.007	 1.978	±	0.019	 2.202	 ‐	 ‐	
221	 Gln	 8.281	±	0.002	 122.044	±	0.021	 56.506	±	0.128 29.762	 4.299	±	0.028	 2.02	±	0.013	 ‐	 ‐	 ‐	
222	 Ser	 8.213	±	0.006	 116.916	±	0.11	 58.492	±	0.012 63.854	 ‐	 3.817	 ‐	 ‐	 ‐	
223	 Ser	 8.322	±	0.009	 117.672	±	0.154	 58.731	±	0.131 63.948	 ‐	 3.899	±	0.02	 ‐	 ‐	 ‐	
224	 Glu	 8.37	±	0.007	 122.597 ±	0.119	 56.784	±	0.054 30.032	±	0.025	 4.25	±	0.012	 1.79	±	0.009	 ‐	 ‐	 ‐	
225	 Lys	 8.181	±	0.003	 121.261	±	0.157	 56.585	±	0.113 32.936	 4.262	±	0.016	 1.735	±	0.011	 ‐	 ‐	 ‐	
226	 Glu	 8.282	±	0.003	 121.292	±	0.072	 57.157	±	0.007 29.807	 4.202	±	0.004	 2.02	±	0.021	 2.223	 ‐	 ‐	
227	 Asn	 8.368	±	0.004	 119.275	±	0.056	 53.357	±	0.041 39.106	±	0.031	 4.159	 2.772	±	0.011	 ‐	 ‐	 ‐	
228	 Asp	 8.302	±	0.008	 121.214	±	0.057	 54.354	±	0.096 41.452	±	0.072	 ‐	 2.675	±	0.013	 ‐	 ‐	 ‐	
229	 Ser	 8.298	±	0.002	 116.311	±	0.091	 58.872	±	0.131 63.95	±	0.134	 4.433	±	0.006	 3.88	±	0.013	 ‐	 ‐	 ‐	
230	 Gly	 8.431	±	0.004	 110.723	±	0.151	 45.496	±	0.068 ‐	 3.965	±	0.021	 ‐	 ‐	 ‐	 ‐	
231	 Thr	 7.959	±	0.006	 113.633	±	0.051	 61.926	±	0.078 70.004	±	0.124	 4.323	±	0.023	 4.03	±	0.005	 1.171	±	0.012	 ‐	 ‐	
232	 Leu	 8.287	±	0.003	 124.764	±	0.116	 55.2	±	0.062 42.366	±	0.151	 4.388	±	0.014	 1.616	±	0.014	 1.585	 0.84	/	0.889	 ‐	
233	 Asp	 7.837	±	0.004	 126.462	±	0.032	 55.802	±	0.053 42.484	±	0.072	 4.337	 2.529	/	2.589	 ‐	 ‐	 ‐	
251	 Ser	 8.284	±	0.004	 119.094	±	0.067	 58.483	±	0.095 63.81	±	0.002	 4.39	±	0.022	 3.84	±	0.015	 ‐	 ‐	 ‐	



















































ECL	 kit	 (Thermo	 Scientific)	 was	 applied	 according	 to	 the	 manufacturer’s	 instructions	 for	





























































































were	prescreened	 for	Taspase	 inhibition	 in	vitro.	Measurements	were	 taken	 in	3	%	DMSO	to	guarantee	
solubility	of	the	compounds	and	referenced	to	a	DMSO	control.	Error	bars	indicate	standard	deviations	from	
two	 independent	 experiments.	 The	 compounds	 are	 listed	 in	 supplemental	 figure	 7.22	 below.	 b	 Two	
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